Learn more about how MIMEDX is driving long-term value for shareholders
Proxy Solicitation Materials and Shareholder Communications for
2021 Annual Meeting of Shareholders
MiMedx is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a core business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MiMedx has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.
May 20, 2021
10:00 AM EDT
Copyright Nasdaq. Minimum 15 minutes delayed.
Data Provided by Refinitiv. Minimum 15 minutes delayed.